Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection.

摘要: Although protease inhibitor (PI) therapy has improved the clinical status of patients with HIV infection, concerns have arisen that such treatment may deleterious effects on glucose control, lipid metabolism, and body fat distribution. To determine whether initiation PI uniquely affects we analyzed paired data in HIV-infected before after beginning antiretroviral included a (PI; N = 20) or lamivudine (3TC) but no (3TC; 9); control group stable regimens neither these agents (CONT: 12). Measurements fasting glucose; insulin; triglycerides; total, high-density lipoprotein (HDL) low-density (LDL) cholesterol; RNA; CD4+ lymphocytes; weight; total regional composition. Neither weight nor content changed significantly any during period observation. Nonetheless, therapy, there were significant increases (+9+/-3 mg/dl; p .0136), insulin (+12.2+/-4.9 U/ml; .023), triglycerides (+53+/-17 .0069), LDL cholesterol (+32+/-11 +18+/-5 .0082 .0026, respectively). None parameters 3TC CONT groups. The groups experienced comparable lymphocytes, suggesting observed metabolic be associated PIs uniquely, rather than improvement status. However, it is also possible are more effective viral suppression, because greater proportion achieved undetectable levels virus. We conclude changes metabolism induced by absence Longer periods follow-up will required to significance changes. at moment, risks do not appear outweigh improvements survival seen therapy.